Viral Hepatitis

You have full text access to this OnlineOpen article

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C†‡

  1. Stefan Zeuzem1,§,*,
  2. Eric M. Yoshida2,
  3. Yves Benhamou3,
  4. Stephen Pianko4,
  5. Vincent G. Bain5,
  6. Daniel Shouval6,
  7. Robert Flisiak7,
  8. Vratislav Rehak8,
  9. Mircea Grigorescu9,
  10. Kelly Kaita10,
  11. Patrick W. Cronin11,
  12. Erik Pulkstenis11,
  13. G. Mani Subramanian11,
  14. John G. McHutchison12

Article first published online: 9 MAY 2008

DOI: 10.1002/hep.22403

Issue

Hepatology

Hepatology

Volume 48, Issue 2, pages 407–417, August 2008

Additional Information

How to Cite

Zeuzem, S., Yoshida, E. M., Benhamou, Y., Pianko, S., Bain, V. G., Shouval, D., Flisiak, R., Rehak, V., Grigorescu, M., Kaita, K., Cronin, P. W., Pulkstenis, E., Subramanian, G. M. and McHutchison, J. G. (2008), Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology, 48: 407–417. doi: 10.1002/hep.22403

Author Information

  1. 1

    J.W. Goethe-University Hospital, Frankfurt, Germany

  2. 2

    University of British Columbia, Vancouver, Canada

  3. 3

    Hôpital Pitié-Salpêtrière, Paris, France

  4. 4

    Monash University Medical School, Victoria, Australia

  5. 5

    University of Alberta, Edmonton, Canada

  6. 6

    Hadassah University, Jerusalem, Israel

  7. 7

    Medical University of Bialystok, Poland

  8. 8

    Spitalul Clinic de Adulti Cluj-Napoca, Romania

  9. 9

    Nuselská Poliklinika–Remedis, Prague, Czech Republic

  10. 10

    University of Manitoba, Winnipeg, Canada

  11. 11

    Human Genome Sciences Inc., Rockville, MD

  12. 12

    Division of Gastroenterology, Duke Clinical Research Institute, Durham, NC

  1. §

    fax: 49-(0)69-6301-6448.

*Direktor der Medizinischen Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

  1. †

    This study is registered on ClinicalTrials.gov (identifier NCT00115908; http://clinicaltrials.gov/ct2/show/NCT00115908?term=human+genome+sciences&rank=2)

  2. ‡

    Potential conflict of interest: Dr. McHutchison is a consultant for and received grants from Anadys, Colsy Pharmaceutical Group, First Circle Medical, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia, Novartis, Pharmasset, Pfizer, Roche, Schering-Plough, Valeant Pharmaceuticals, Vertex Pharmaceuticals, and Wyeth. He received grants from Globe Immune, Medtronics, Salix Pharmaceuticals, and Sanofi-Aventis. He is also a consultant for Biolex, Epiphany Biosciences, InterMune Pharmaceuticals, National Genetics Institute, Peregrine, and United Therapeutics. Drs. Subramanian, Cronin and Pulkstenis own stock in Human Genome Sciences, Inc. Dr. Kaita is a consultant for, is on the speakers' bureau of, and received grants from Schering-Plough, Roche, and Gilead. Dr. Zeuzem is a consultant for, is on the speakers' bureau of, and received grants from Human Genome Sciences, Novartis, Roche, and Schering-Plough. Dr. Yoshida received grants from and advises Hoffmann-La Roche. He also received grants from Schering-Plough, GlaxoSmithKline, Ortho Janssen, Pfizer, Gilead Sciences, and Cangene. He advises Novartis. Dr. Benhamou is a consultant for and is on the speakers' bureau of Human Genome Science and Roche. Dr. Pianko is a consultant for, advises, and is on the speakers' bureau of Human Genome Sciences, Novartis, and Roche. Dr. Bain is a consultant for Human Genome Sciences. Dr. Shouval received grants from Human Genome Sciences. Dr. Flisiak received grants from Debiopharm. He advises and received grants from Human Genome Sciences and Roche.

Publication History

  1. Issue published online: 29 JUL 2008
  2. Article first published online: 9 MAY 2008
  3. Accepted manuscript online: 9 MAY 2008 12:00AM EST
  4. Manuscript Accepted: 25 APR 2008
  5. Manuscript Received: 21 FEB 2008

Funded by

  • Human Genome Sciences Inc., Rockville, MD
  • Novartis Pharma AG, Basel, Switzerland

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (528K)

References

  • 1
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331–338.
    Direct Link:
  • 2
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–567.
  • 3
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704–708.
    Direct Link:
  • 4
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 5
    Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675–681.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965.
  • 7
    McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140–147.
  • 8
    Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341–349.
  • 9
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS International Study Group. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 10
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370–381.
  • 11
    Liu C, Zhu H, Subramanian GM, Moore PA, Xu Y, Nelson DR. Anti-HCV activity of albinterferon alfa-2b in cell culture. Hepatol Res 2007; 37: 941–947.
    Direct Link:
  • 12
    Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671–678.
  • 13
    Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006; 11: 35–45.
  • 14
    Ware JE, Kosinski M. The SF-36 Health Survey (version 2.0) Technical Note. Boston, MA: Health Assessment Lab, September 20, 1996 (updates September 27, 1997).
  • 15
    Ware JE, Snow KK, Kosinski MA, Gandek B. SF-36 Health Survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
  • 16
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–433.
  • 17
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645–652.
    Direct Link:
  • 18
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954–960.
    Direct Link:
  • 19
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.
  • 20
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704–708.
    Direct Link:
View Full Article (HTML) Get PDF (528K)